Symbols / TARA $5.10 +0.49% Protara Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TARA Chart
About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 275.56M
Enterprise Value 122.01M Income -57.44M Sales —
Book/sh 3.67 Cash/sh 2.88 Dividend Yield —
Payout 0.00% Employees 46 IPO —
P/E — Forward P/E -3.66 PEG —
P/S — P/B 1.39 P/C —
EV/EBITDA -1.90 EV/Sales — Quick Ratio 14.34
Current Ratio 14.58 Debt/Eq 1.71 LT Debt/Eq —
EPS (ttm) -1.34 EPS next Y -1.39 EPS Growth —
Revenue Growth — Earnings 2026-05-07 ROA -20.64%
ROE -31.60% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 54.08M
Shs Float 47.46M Short Float 12.04% Short Ratio 4.65
Short Interest — 52W High 7.82 52W Low 2.77
Beta 1.50 Avg Volume 1.10M Volume 262.61K
Target Price $25.71 Recom None Prev Close $5.07
Price $5.09 Change 0.49%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.71
Mean price target
2. Current target
$5.13
Latest analyst target
3. DCF / Fair value
$-12.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.13
Low
$23.00
High
$30.00
Mean
$25.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-04 init JP Morgan — → Overweight $27
2026-02-10 reit HC Wainwright & Co. Buy → Buy $23
2026-01-07 init Piper Sandler — → Overweight $24
2025-12-03 reit HC Wainwright & Co. Buy → Buy $23
2025-11-19 reit HC Wainwright & Co. Buy → Buy $23
2025-05-22 init Jones Trading — → Buy $21
2025-04-28 reit HC Wainwright & Co. Buy → Buy $23
2025-04-16 init Scotiabank — → Sector Outperform $12
2025-03-14 init Cantor Fitzgerald — → Overweight —
2025-03-11 init LifeSci Capital — → Outperform $22
2025-03-06 reit HC Wainwright & Co. Buy → Buy $23
2024-12-06 reit Guggenheim Buy → Buy $20
2024-12-06 reit HC Wainwright & Co. Buy → Buy $23
2024-11-14 reit HC Wainwright & Co. Buy → Buy $23
2024-08-12 main Oppenheimer Outperform → Outperform $25
2024-08-08 reit HC Wainwright & Co. Buy → Buy $23
2024-05-06 reit HC Wainwright & Co. Buy → Buy $23
2024-04-22 main Oppenheimer Outperform → Outperform $30
2024-04-08 main HC Wainwright & Co. Buy → Buy $23
2024-03-14 reit HC Wainwright & Co. Buy → Buy $23
News
RSS: Latest TARA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 ZUMMO JACQUELINE Officer — 22,598 $5.26 $118,865
2026-01-16 NICACIO LEONARDO VIANA M.D. Officer — 26,000 $0.00 $0
2026-01-16 FABBIO PATRICK Chief Financial Officer — 28,000 $0.00 $0
2026-01-16 SHEFFERMAN JESSE M Chief Executive Officer — 87,000 $0.00 $0
2026-01-16 ZUMMO JACQUELINE Chief Operating Officer — 30,000 $0.00 $0
2026-01-16 CONKLING WILLIAM Officer — 26,000 $0.00 $0
2026-01-16 FRY HANNAH Officer — 9,500 $0.00 $0
2025-06-27 SHEFFERMAN JESSE M Chief Executive Officer — 18,667 $0.00 $0
2025-06-24 SHEFFERMAN JESSE M Chief Executive Officer — 300,000 $0.00 $0
2025-06-02 CONKLING WILLIAM Officer — 50,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
64.55
+31.32%
49.15
+12.70%
43.61
+16.16%
37.55
Research And Development
42.63
+34.47%
31.70
+26.87%
24.99
+48.67%
16.81
Selling General And Administration
21.92
+25.59%
17.45
-6.30%
18.62
-10.19%
20.74
General And Administrative Expense
21.92
+25.59%
17.45
-6.30%
18.62
-10.19%
20.74
Other Gand A
21.92
+25.59%
17.45
-6.30%
18.62
-10.19%
20.74
Total Expenses
64.55
+31.32%
49.15
+12.70%
43.61
+16.16%
37.55
Operating Income
-64.55
-31.32%
-49.15
-12.70%
-43.61
-16.16%
-37.55
Total Operating Income As Reported
-64.55
-31.32%
-49.15
-12.70%
-43.61
+34.97%
-67.06
EBITDA
-64.19
-31.47%
-48.82
-12.83%
-43.27
+32.98%
-64.57
Normalized EBITDA
-64.24
-31.47%
-48.86
-12.88%
-43.28
-23.43%
-35.07
Reconciled Depreciation
0.36
+9.04%
0.33
-2.64%
0.34
+37.50%
0.25
EBIT
-64.55
-31.32%
-49.15
-12.70%
-43.61
+32.71%
-64.81
Total Unusual Items
0.05
+36.11%
0.04
+200.00%
0.01
+100.04%
-29.50
Total Unusual Items Excluding Goodwill
0.05
+36.11%
0.04
+200.00%
0.01
+100.04%
-29.50
Special Income Charges
—
—
0.00
+100.00%
-29.52
Impairment Of Capital Assets
—
—
0.00
-100.00%
29.52
Net Income
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Pretax Income
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Net Non Operating Interest Income Expense
6.33
+53.11%
4.13
+29.99%
3.18
+191.03%
1.09
Interest Expense Non Operating
—
—
—
1.14
Net Interest Income
6.33
+53.11%
4.13
+29.99%
3.18
+191.03%
1.09
Interest Expense
—
—
—
1.14
Interest Income Non Operating
6.33
+53.11%
4.13
+29.99%
3.18
+42.65%
2.23
Interest Income
6.33
+53.11%
4.13
+29.99%
3.18
+42.65%
2.23
Other Income Expense
0.78
+84.16%
0.42
+3425.00%
0.01
+100.04%
-29.50
Other Non Operating Income Expenses
0.73
+88.63%
0.39
—
—
Gain On Sale Of Security
0.05
+36.11%
0.04
+200.00%
0.01
-29.41%
0.02
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Net Income From Continuing Operation Net Minority Interest
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Net Income From Continuing And Discontinued Operation
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Net Income Continuous Operations
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Normalized Income
-57.49
-28.80%
-44.63
-10.39%
-40.43
-10.92%
-36.45
Net Income Common Stockholders
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Diluted EPS
—
-2.17
+39.22%
-3.57
+39.08%
-5.86
Basic EPS
—
-2.17
+39.22%
-3.57
+39.08%
-5.86
Basic Average Shares
—
20.59
+81.73%
11.33
+0.64%
11.26
Diluted Average Shares
—
20.59
+81.73%
11.33
+0.64%
11.26
Diluted NI Availto Com Stockholders
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Line Item Trend 2023-12-31
Total Assets
78.95
Current Assets
68.70
Cash Cash Equivalents And Short Term Investments
65.58
Cash And Cash Equivalents
39.59
Other Short Term Investments
25.99
Receivables
0.24
Accrued Interest Receivable
0.24
Prepaid Assets
2.85
Restricted Cash
—
Other Current Assets
0.04
Total Non Current Assets
10.25
Net PPE
6.56
Gross PPE
7.38
Accumulated Depreciation
-0.82
Properties
0.00
Machinery Furniture Equipment
0.60
Other Properties
6.23
Leases
0.55
Goodwill And Other Intangible Assets
2.66
Goodwill
—
Other Intangible Assets
2.66
Investments And Advances
0.00
Non Current Prepaid Assets
0.27
Other Non Current Assets
0.76
Total Liabilities Net Minority Interest
10.63
Current Liabilities
6.15
Payables And Accrued Expenses
3.05
Payables
2.43
Accounts Payable
2.43
Current Accrued Expenses
0.62
Pensionand Other Post Retirement Benefit Plans Current
2.11
Total Tax Payable
—
Current Debt And Capital Lease Obligation
0.98
Current Capital Lease Obligation
0.98
Total Non Current Liabilities Net Minority Interest
4.48
Long Term Debt And Capital Lease Obligation
4.48
Long Term Capital Lease Obligation
4.48
Stockholders Equity
68.32
Common Stock Equity
68.32
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
11.36
Ordinary Shares Number
11.36
Treasury Shares Number
0.00
Additional Paid In Capital
268.73
Retained Earnings
-200.38
Gains Losses Not Affecting Retained Earnings
-0.03
Other Equity Adjustments
-0.03
Total Equity Gross Minority Interest
68.32
Total Capitalization
68.32
Working Capital
62.56
Invested Capital
68.32
Total Debt
5.47
Capital Lease Obligations
5.47
Net Tangible Assets
65.66
Tangible Book Value
65.66
Available For Sale Securities
—
Investmentin Financial Assets
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-56.37
-57.41%
-35.81
+4.66%
-37.56
-41.95%
-26.46
Cash Flow From Continuing Operating Activities
-56.37
-57.41%
-35.81
+4.66%
-37.56
-41.95%
-26.46
Net Income From Continuing Operations
-57.44
-28.80%
-44.60
-10.33%
-40.42
+38.71%
-65.95
Depreciation Amortization Depletion
0.36
+9.04%
0.33
-2.64%
0.34
+37.50%
0.25
Depreciation
0.36
+9.04%
0.33
-2.64%
0.34
+37.50%
0.25
Depreciation And Amortization
0.36
+9.04%
0.33
-2.64%
0.34
+37.50%
0.25
Other Non Cash Items
1.08
+7.14%
1.01
-0.39%
1.01
-25.84%
1.37
Stock Based Compensation
3.83
-7.25%
4.12
-32.29%
6.09
-8.91%
6.69
Asset Impairment Charge
—
—
0.00
-100.00%
29.52
Operating Gains Losses
-0.01
—
—
—
Gain Loss On Investment Securities
-0.01
—
—
—
Change In Working Capital
-2.94
-173.40%
4.01
+196.81%
-4.14
-867.90%
0.54
Change In Prepaid Assets
-2.09
-265.37%
1.26
+199.76%
-1.26
-577.36%
0.27
Change In Payables And Accrued Expense
-0.05
-101.28%
4.06
+1082.80%
0.34
-75.13%
1.38
Change In Accrued Expense
0.82
-69.32%
2.68
+629.90%
-0.51
-167.51%
0.75
Change In Payable
-0.87
-163.22%
1.38
+62.85%
0.85
+34.39%
0.63
Change In Account Payable
-0.87
-163.22%
1.38
+62.85%
0.85
+34.39%
0.63
Change In Other Current Assets
0.32
+198.17%
-0.33
+85.74%
-2.30
-1136.04%
0.22
Change In Other Current Liabilities
-1.12
-14.23%
-0.98
-7.31%
-0.92
+30.90%
-1.33
Investing Cash Flow
-139.49
-828.22%
19.16
-63.93%
53.11
+255.23%
14.95
Cash Flow From Continuing Investing Activities
-139.49
-828.22%
19.16
-63.93%
53.11
+255.23%
14.95
Net PPE Purchase And Sale
-0.09
-49.21%
-0.06
-40.00%
-0.04
+62.50%
-0.12
Purchase Of PPE
-0.09
-49.21%
-0.06
-40.00%
-0.04
+62.50%
-0.12
Capital Expenditure
-0.09
-49.21%
-0.06
-40.00%
-0.04
+62.50%
-0.12
Net Investment Purchase And Sale
-139.40
-825.35%
19.22
-63.84%
53.15
+252.70%
15.07
Purchase Of Investment
-204.63
-596.45%
-29.38
-141.11%
-12.19
+72.02%
-43.55
Sale Of Investment
65.23
+34.23%
48.60
-25.62%
65.34
+11.46%
58.62
Financing Cash Flow
82.72
-40.86%
139.87
+153797.80%
-0.09
-1.11%
-0.09
Cash Flow From Continuing Financing Activities
82.72
-40.86%
139.87
+153797.80%
-0.09
-1.11%
-0.09
Net Issuance Payments Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
80.96
-40.47%
136.01
0.00
+100.00%
-0.09
Common Stock Payments
—
—
-0.09
-1.11%
-0.09
Repurchase Of Capital Stock
—
—
-0.09
-1.11%
-0.09
Proceeds From Stock Option Exercised
2.55
-35.31%
3.94
0.00
—
Net Other Financing Charges
-0.80
-862.65%
-0.08
+8.79%
-0.09
—
Changes In Cash
-113.14
-191.83%
123.21
+697.02%
15.46
+233.30%
-11.60
Beginning Cash Position
163.54
+305.50%
40.33
+62.15%
24.87
-31.80%
36.47
End Cash Position
50.40
-69.18%
163.54
+305.50%
40.33
+62.15%
24.87
Free Cash Flow
-56.46
-57.39%
-35.87
+4.60%
-37.60
-41.48%
-26.58
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Amortization Of Securities
-1.25
-81.75%
-0.69
-54.28%
-0.44
-139.05%
1.14
Common Stock Issuance
80.96
-40.47%
136.01
0.00
—
Issuance Of Capital Stock
80.96
-40.47%
136.01
0.00
—
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category